New Modalities for the Administration of Inhaled Nitric Oxide in Intensive Care Units After Cardiac Surgery or for Neonatal Indications: A Prospective Observational Study.
[en] BACKGROUND: Nitric oxide (NO) has a well-known efficacy in pulmonary hypertension (PH), with wide use for 20 years in many countries. The objective of this study was to describe the current use of NO in real life and the gap with the guidelines. METHODS: This is a multicenter, prospective, observational study on inhaled NO administered through an integrated delivery and monitoring device and indicated for PH according to the market authorizations. The characteristics of NO therapy and ventilation modes were observed. Concomitant pulmonary vasodilator treatments, safety data, and outcome were also collected. Quantitative data are expressed as median (25th, 75th percentile). RESULTS: Over 1 year, 236 patients were included from 14 equipped and trained centers: 117 adults and 81 children with PH associated with cardiac surgery and 38 neonates with persistent PH of the newborn. Inhaled NO was initiated before intensive care unit (ICU) admission in 57%, 12.7%, and 38.9% with an initial dose of 10 (10, 15) ppm, 20 (18, 20) ppm, and 17 (11, 20) ppm, and a median duration of administration of 3.9 (1.9, 6.1) days, 3.8 (1.8, 6.8) days, and 3.1 (1.0, 5.7) days, respectively, for the adult population, pediatric cardiac group, and newborns. The treatment was performed using administration synchronized to the mechanical ventilation. The dose was gradually decreased before withdrawal in 86% of the cases according to the usual procedure of each center. Adverse events included rebound effect for 3.4% (95% confidence interval [CI], 0.9%-8.5%) of adults, 1.2% (95% CI, 0.0%-6.7%) of children, and 2.6% (95% CI, 0.1%-13.8%) of neonates and methemoglobinemia exceeded 2.5% for 5 of 62 monitored patients. Other pulmonary vasodilators were associated with NO in 23% of adults, 95% of children, and 23.7% of neonates. ICU stay was respectively 10 (6, 22) days, 7.5 (5.5, 15) days, and 9 (8, 15) days and ICU mortality was 22.2%, 6.2%, and 7.9% for adults, children, and neonates, respectively. CONCLUSIONS: This study confirms the safety of NO therapy in the 3 populations with a low rate of rebound effect. Gradual withdrawal of NO combined with pulmonary vasodilators are current practices in this population. The use of last-generation NO devices allowed good compliance with recommendations.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Gaudard, Philippe
Barbanti, Claudio
Rozec, Bertrand
Mauriat, Philippe
M'rini, Mimoun
Cambonie, Gilles
Liet, Jean Michel
Girard, Claude
Leger, Pierre Louis
Assaf, Ziad
Damas, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Soins Intensifs Généraux
New Modalities for the Administration of Inhaled Nitric Oxide in Intensive Care Units After Cardiac Surgery or for Neonatal Indications: A Prospective Observational Study.
Publication date :
2018
Journal title :
Anesthesia and Analgesia
ISSN :
0003-2999
eISSN :
1526-7598
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Girard C, Lehot JJ, Pannetier JC, Filley S, Ffrench P, Estanove S. Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension. Anesthesiology. 1992;77:880-883.
Barr FE, Macrae D. Inhaled nitric oxide and related therapies. Pediatr Crit Care Med. 2010;11(suppl 2):S30-S36.
Germann P, Braschi A, Della Rocca G, et al. Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Med. 2005;31:1029-1041.
Elmi-Sarabi M, Deschamps A, Delisle S, et al. Aerosolized vasodilators for the treatment of pulmonary hypertension in cardiac surgical patients: A systematic review and meta-analysis. Anesth Analg. 2017;125:393-402.
Roberts JD Jr, Fineman JR, Morin FC III, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. N Engl J Med. 1997;336:605-610.
Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: A randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/ PPHN Study Group. Pediatrics. 1998;101:325-334.
Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: Current strategies in children with congenital heart disease. Cardiology. 2010;116:10-17.
Beloucif S, Payen D. A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine. Intensive Care Med. 1998;24:864-877.
Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg. 2005;20:171-176.
Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: A prospective randomized trial. J Cardiothorac Vasc Anesth. 2008;22:406-413.
Matamis D, Pampori S, Papathanasiou A, et al. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: Acute effects on postoperative gas exchange and hemodynamics. Circ Heart Fail. 2012;5:47-53.
Ruan SY, Wu HY, Lin HH, Wu HD, Yu CJ, Lai MS. Inhaled nitric oxide and the risk of renal dysfunction in patients with acute respiratory distress syndrome: A propensity-matched cohort study. Crit Care. 2016;20:389.
Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016.CD002787. doi:10.1002/14651858.CD002787.pub3.
Afshari A, Brok J, Møller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: A systematic review with meta-analysis and trial sequential analysis. Anesth Analg. 2011;112:1411-1421.
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42-D50.
Fernandes JL, Sampaio RO, Brandão CM, et al. Comparison of inhaled nitric oxide versus oxygen on hemodynamics in patients with mitral stenosis and severe pulmonary hypertension after mitral valve surgery. Am J Cardiol. 2011;107:1040-1045.
Benedetto M, Romano R, Baca G, et al. Inhaled nitric oxide in cardiac surgery: Evidence or tradition?. Nitric Oxide. 2015;49:67-79.
Troncy E, Francoeur M, Blaise G. Inhaled nitric oxide: Clinical applications, indications, and toxicology. Can J Anaesth. 1997;44:973-988.
Kilchemmann Fuentes C, Vallejos Vallejos C, Román Navarro A. [Cost effectiveness and budget impact analysis of inhaled nitric oxide in a neonatal unit from the perspective of the public health system]. Rev Chil Pediatr. 2016;87:463-467.
Cueto E, López-Herce J, Sánchez A, Carrillo A. Life-threatening effects of discontinuing inhaled nitric oxide in children. Acta Paediatr. 1997;86:1337-1339.
Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med. 1996;153:1985-1987.
Christenson J, Lavoie A, O'Connor M, Bhorade S, Pohlman A, Hall JB. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med. 2000;161:1443-1449.
Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006;174:1042-1047.
Morel AA, Shreck E, Mally PV, Kim Y, Bailey SM, Wachtel EV. Clinical characteristics and factors associated with term and late preterm infants that do not respond to inhaled nitric oxide (iNO). J Perinat Med. 2016;44:663-668.
Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J. 2004;25:1651-1656.
Kageyama K, Shime N, Hirose M, Hiramatsu N, Ashida H, Hashimoto S. Factors contributing to successful discontinuation from inhaled nitric oxide therapy in pediatric patients after congenital cardiac surgery. Pediatr Crit Care Med. 2004;5:351-355.
Kaestner M, Schranz D, Warnecke G, Apitz C, Hansmann G, Miera O. Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016;102(suppl 2):ii57-ii66.
Petit PC, Fine DH, Vásquez GB, Gamero L, Slaughter MS, Dasse KA. The pathophysiology of nitrogen dioxide during inhaled nitric oxide therapy. ASAIO J. 2017;63:7-13.
Hermon MM, Burda G, Golej J, et al. Methemoglobin formation in children with congenital heart disease treated with inhaled nitric oxide after cardiac surgery. Intensive Care Med. 2003;29:447-452.
Kuch BA, Saville AL, Sanchez De Toledo J, Venkataraman ST. Inhaled pulmonary vasodilators: Are there indications within the pediatric ICU?. Respir Care. 2017;62:678-698.